Premium
Recent advances in the chemotherapy of metastatic osteogenic sarcoma
Author(s) -
Jaffe Norman
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h
Subject(s) - medicine , nausea , vomiting , methotrexate , sarcoma , chemotherapy , surgery , stomatitis , oncology , pathology
High doses of methotrexate with citrovorum factor were administered to 10 patients with metastatic osteogenic sarcoma. A complete regression of pulmonary metastases was obtained in two patients and partial regression of tumor in two others. Side effects included nausea, vomiting, abdominal pain, stomatitis, bone marrow suppression, skin lesions, and renal impairment responding to additional citrovorum factor. The duration of response varied from 1 to 8+ months with complete regression of tumor persisting in one patient. Alternative schedules of methotrexate‐citrovorum administration produced an additional response in one patient. Further studies with this maneuver are under investigation.